VIRAX BIOLABS GROUP LTD

Profile

Company Names

VIRAX BIOLABS GROUP LTD

Addresses

BIOCITY GLASGOW, BO-NESS ROAD NEWHOUSE, LANARKSHIRE, X0 ML1 SUH

20 NORTH AUDLEY STREET, LONDON, X0 W1K 6LX

Phone Numbers

44 020 7788 7414

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2021

State Incorporated:

CAYMAN ISLANDS

Total Amount Raised:

$11,150,000.00

Number of Funding Rounds:

3
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
3
2025-12-03 
$5,000,000.00 
$5,000,000.00 
$0.00 
 
2
2023-10-12 
$2,150,000.00 
$2,150,000.00 
$0.00 
Equity 
1
2023-03-10 
$4,000,000.00 
$4,000,000.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
JASON 
 
DAVIS 
EXECUTIVE OFFICER
PARTICLE DRILLING TECHNOLOGIES INC/NV   |  HYPERDYNAMICS CORP   |  SUCCESS RESOURCES GLOBAL LTD.   |  RADICO, INC.   |  SIMON DATA, INC.   |  SEI - BOSTON LLC   |  SECURED FIXED INCOME FUND, LLC   |  VIRAX BIOLABS GROUP LTD   |  NCBP REIT LLC
YAIR 
 
EREZ 
DIRECTOR
VIRAX BIOLABS GROUP LTD
JAMES 
 
FOSTER 
EXECUTIVE OFFICER, DIRECTOR
GREYCOURT PARTNERS FUND L.P.   |  RISKIVE, INC.   |  AGRIOS GLOBAL HOLDINGS LTD.   |  VIRAX BIOLABS GROUP LTD
JAMES 
ALEXANDER CUNLIFFE 
FOSTER 
EXECUTIVE OFFICER, DIRECTOR
VIRAX BIOLABS GROUP LTD
TOMASZ 
 
GEORGE 
EXECUTIVE OFFICER
VIRAX BIOLABS GROUP LTD
NELSON 
 
HAIGHT 
DIRECTOR
VIRAX BIOLABS GROUP LTD
NELSON 
MAURICE 
HAIGHT 
DIRECTOR
VIRAX BIOLABS GROUP LTD
NIGEL 
 
MCCRACKEN 
EXECUTIVE OFFICER, DIRECTOR
VIRAX BIOLABS GROUP LTD
EVAN 
 
NORTON 
DIRECTOR
NEUROPACE INC   |  ENDOGASTRIC SOLUTIONS INC   |  LEVITA MAGNETICS INTERNATIONAL CORP.   |  VIRAX BIOLABS GROUP LTD   |  SPRIG EQUITY WAREHOUSING FUND I, LLC   |  SPRIG EQUITY OPPORTUNITIES SPV, LLC   |  SPRIG EQUITY SPM SPV, LLC   |  SPRIG EQUITY PC SPV, LLC
CAMERON 
 
SHAW 
EXECUTIVE OFFICER, DIRECTOR
VIRAX BIOLABS GROUP LTD
MARK 
 
TERNOUTH 
EXECUTIVE OFFICER, DIRECTOR
VIRAX BIOLABS GROUP LTD
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2025-12-18
D
Link
BIOTECHNOLOGY 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
NO REVENUES 
 
2025-12-03 
2023-10-17
D
Link
BIOTECHNOLOGY 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
$1 - $1,000,000 
Equity 
2023-10-12 
2023-03-15
D
Link
BIOTECHNOLOGY 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
$1 - $1,000,000 
Equity 
2023-03-10 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
H.C. WAINWRIGHT + CO., LLC
375
NONE
NONE
H.C. WAINWRIGHT + CO., LLC
375
NONE
NONE
H.C. WAINWRIGHT + CO.
375